Academic literature on the topic 'Vessie hyperactive'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Vessie hyperactive.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Vessie hyperactive":
Geoffrion, Roxana, Danny Lovatsis, Jens-Erik Walter, Queena Chou, William Easton, Annette Epp, Roxana Geoffrion, et al. "Traitements visant la vessie hyperactive : Accent sur la pharmacothérapie." Journal of Obstetrics and Gynaecology Canada 34, no. 11 (November 2012): 1102–4. http://dx.doi.org/10.1016/s1701-2163(16)35441-x.
Geoffrion, Roxana. "Traitements visant la vessie hyperactive : Accent sur la pharmacothérapie." Journal of Obstetrics and Gynaecology Canada 38, no. 12 (December 2016): S158—S170. http://dx.doi.org/10.1016/j.jogc.2016.09.027.
Geoffrion, Roxana. "N o 283-Traitements visant la vessie hyperactive : Accent sur la pharmacothérapie." Journal of Obstetrics and Gynaecology Canada 40, no. 1 (January 2018): e33-e44. http://dx.doi.org/10.1016/j.jogc.2017.11.006.
Bolduc, S., A. Fortin, V. Morin, and P. Gervais. "P-032 – Observance au traitement chez les enfants atteints de vessie hyperactive." Archives de Pédiatrie 22, no. 5 (May 2015): 241. http://dx.doi.org/10.1016/s0929-693x(15)30217-7.
Geoffrion, Roxana. "N o 353 – Traitements visant la vessie hyperactive : Accent sur la pharmacothérapie – Addenda." Journal of Obstetrics and Gynaecology Canada 39, no. 12 (December 2017): 1230–39. http://dx.doi.org/10.1016/j.jogc.2017.08.042.
Zenner-Weber, Marietta. "Les symptômes d’urgence mictionnelle en cas de vessie hyperactive ont un retentissement considérable sur la qualité de vie." Revue Médicale Suisse 5, no. 196 (2009): 687. http://dx.doi.org/10.53738/revmed.2009.5.196.0687.
Leon, P., A. Binet, C. Jolly, and M. L. Poli-Merol. "Usage de la toxine botulique dans les vessies hyperactives non neurologiques chez l’enfant." Progrès en Urologie 22, no. 13 (November 2012): 758. http://dx.doi.org/10.1016/j.purol.2012.08.041.
Denys, P., E. Chartier-Kastler, P. Azouvi, O. Remy-Neris, and B. Bussel. "Effet urodynamique de la neurostimulation S3 test sur les vessies hyperactives résistantes des blessés médullaires." Annales de Réadaptation et de Médecine Physique 41, no. 6 (January 1998): 348. http://dx.doi.org/10.1016/s0168-6054(98)80142-6.
Amarenco, G., A. Le Cocquen, D. Lagauche, M. Chevignard, and S. Bosc. "Étude cystomanométrique de 153 vessies neurologiques hyperactives avant et après test au bromure de prifinium." Annales de Réadaptation et de Médecine Physique 41, no. 7 (January 1998): 417–20. http://dx.doi.org/10.1016/s0168-6054(98)80263-8.
Lardon, Renaud, and Alain Ruffion. "Quelles peuvent être les futures applications de la toxine botulique en urologie en dehors des vessies hyperactives des patients neurologiques ?" Progrès en Urologie - FMC 19, no. 3 (September 2009): F91—F94. http://dx.doi.org/10.1016/j.fpurol.2009.02.003.
Dissertations / Theses on the topic "Vessie hyperactive":
Biardeau, Xavier. "Optimisation des thérapies de stimulation/modulation électrique dans le traitement des troubles vésico-sphinctériens neurogènes et non-neurogènes." Electronic Thesis or Diss., Université de Lille (2022-....), 2024. http://www.theses.fr/2024ULILS014.
Even if it involves alternating between a filling phase and an emptying phase, the normal micturition cycle cannot be summed up as a binary operation but involves the constant consideration of multiple factors: the filling level of the bladder reservoir, the safety of the environment in which we live, the emotional context in which we evolve and the social constraints to which we are subjected.We now know that there are alterations and/or modifications in brain activity and connectivity, as well as changes in the regulation of the autonomic nervous system, in certain types of lower urinary tract dysfunction - notably in overactive bladder or urge urinary incontinence and in certain types of voiding dysfunctions. Among the therapies available today, electrical modulation/stimulation therapies (tibial neurostimulation and sacral neuromodulation) appear able to normalize and/or modify brain activity and connectivity, as well as ANS balance. They could thus provide at least a partial response to some of the etiopathogenies underlying these lower urinary tract dysfunctions. However, the deployment and positioning of these electrical modulation/stimulation therapies are still limited by an incomplete understanding of their mechanisms of action, imperfect identification of the indications and populations most likely to benefit from these therapies, a lack of consensus on the setting of the electrical current delivered, and a lack of medium and long-term evaluation. In the first part, we questioned the indications for these therapies, and particularly their place as a preventive approach for lower urinary tract dysfunctions due to spinal cord injury. We also questioned the relation, in terms of efficacy, between transcutaneous tibial neurostimulation and sacral neuromodulation, to better support patients in shared medical decision-making processe. Finally, we developed the first tool to predict the success of sacral neuromodulation as a treatment for voiding dysfunction. In the second part, we questioned the mechanisms of action, and more specifically the changes in the balance of the autonomic nervous system in response to an acute S3 sacral root stimulation.In the third part, we questioned the mid-term follow-up (5 years) after definitive implantation of sacral neuromodulation in a geographic population pool, looking for risk factors for discontinuation of follow-up. These data, although still to be supplemented by future research projects, will enable us to further optimize electrical modulation/stimulation therapies in the management of neurogenic and non-neurogenic lower urinary tract dysfunctions